The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
CORONARY INTERVENTIONS
Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI
EuroIntervention 2018;14:e426-e433 published online ahead of print May 2018 published online e-edition July 2018. DOI: 10.4244/EIJ-D-18-00335
Ruben Y.G. Tijssen1, MD; Robin P. Kraak1,2, MD; Sjoerd H. Hofma3, MD, PhD; Rene J. van der Schaaf2, MD, PhD; E. Karin Arkenbout4, MD, PhD; Auke Weevers5, MD; Joelle Elias1, MD; Ivo M. van Dongen1, MD; Karel T. Koch1, MD, PhD; Jan Baan Jr1, MD, PhD; M. Marije Vis1, MD, PhD; Robbert J. de Winter1, MD, PhD; Jan J. Piek1, MD, PhD; Jan G.P. Tijssen1, PhD; Jose P.S. Henriques1, MD, PhD; Joanna J. Wykrzykowska1*, MD, PhD
1. AMC Heartcenter, Academic Medical Center - University of Amsterdam, Amsterdam, the Netherlands; 2. Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; 3. Department of Cardiology, Medical Center Leeuwarden, Leeuwarden, the
Aims: The aim of this report of the AIDA trial is to provide full two-year outcomes for the primary endpoint of target vessel failure (TVF) and an update on device thrombosis.